Posts Tagged ‘tirzepatide’

It would be hard to find a sharper contrast than the one displayed yesterday in the report of fourth quarter 2025 business results for Eli Lilly and Novo Nordisk. Lilly is enjoying the best of times. Novo is suffering the worst. “Eli Lilly’s GLP-1 growth is only getting started,” says CNBC, “as Novo Nordisk braces […]

Usually, when new medicines have been on the market for a time, warnings tend to accumulate in the prescription labeling. So it is a bit unusual to see the FDA move to remove a warning. But recently, that’s exactly what happened with semaglutide and tirzepatide. FDA is making a course correction on warnings about suicidal […]

It is no secret that alcohol use disorder is a risk after metabolic and bariatric surgery. The risk rises as time passes after surgery, with one study finding three percent of patients followed for a median of six years having one alcohol use disorder diagnosis in their medical records. Another study found that three years […]

We’ve had a lot to write about this year and you, our readers, have been doing a lot of reading. This running commentary is simply a labor of love. We don’t sell advertising or anything else here, but we do take pleasure when you read what we write and we do pay attention. So with […]

News from Lilly about orforglipron this week points to what might be the next big development for GLP-1 medicines. The company announced topline results for a weight maintenance study of orforglipron and this first glimpse has us thinking that maintain might be the magic word in obesity care next year. The topline come from the […]

Truveta this week published data that reveals striking growth in the use of GLP-1s by women with PCOS (polycystic ovary syndrome). Prescriptions for semaglutide or tirzepatide have risen by more than 700% in women with PCOS, according to their analysis. So don’t think that this is slipping right by the bean counters at drug benefit […]

An important new study in Nature Medicine yesterday gave us a unique view of food noise at a source deep within the brain. Researchers implanted electrodes in the nucleus accumbens of a single subject to monitor brain activity in that region of the brain. The subject had a history of severe obesity and distressing preoccupation […]

This is a perilous and exciting time for investing in obesity innovation as the market for treating this disease advances dramatically. On the side of excitement, we note that the David Wainer in the Wall Street Journal predicts that “obesity drugs are about to go mass market.” Perilous for Novo On the side of peril, […]

President Trump held a press event yesterday to issue some very welcome news on coverage and prices for obesity medicines. On prices, they are coming down. In reality, this is an extension of the ongoing trend of downward pressure on these prices that has been in play since the day that semaglutide and tirzepatide launched […]

Yesterday’s news from the business of developing and selling obesity medicines reveals a lot. Lilly told us tirzepatide is now the biggest-selling drug of any kind in the world and Novo Nordisk started a highly unusual bidding war with Pfizer for Metsera. Metsera is a biotech startup focused on obesity medicines. Booming Tirzepatide Lilly announced […]